Form 4: Gilead Sciences Executive Awarded Stock and Restricted Stock Units

Gilead Sciences' Chief Medical Officer, Merdad Parsey, received common stock and restricted stock units on December 10, 2024.

Summary

• Merdad Parsey, the Chief Medical Officer of Gilead Sciences, Inc., was granted common stock and restricted stock units on December 10, 2024.
• He received 3,820 shares of common stock.
• Additionally, he was granted 82,850 restricted stock units.
• These restricted stock units vest over a four-year period.
• 25% of the restricted stock units will vest on the first anniversary of the grant date.
• The remaining 75% will vest quarterly at a rate of 6.25% until fully vested.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally positive for aligning management and shareholder interests. There are no negative implications.

Positives

• The grant of stock and restricted stock units to the Chief Medical Officer aligns his interests with the long-term success of the company.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The restricted stock units will vest over the next four years, incentivizing the executive's continued service and performance.

Industry Context

Stock and restricted stock unit grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock-based compensation is a standard practice among large pharmaceutical companies like Pfizer, AbbVie, and Johnson & Johnson.
• Vesting schedules, such as the four-year schedule used by Gilead, are also common to ensure long-term alignment of executive interests with shareholder value.
• The specific number of shares and units granted would be dependent on the executive's role and the company's overall compensation strategy, which is not detailed in this document.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning executive interests with long-term company performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

Gilead Sciences, stock, restricted stock units, executive compensation, vesting, Merdad Parsey, Chief Medical Officer